CHARTER ON ACCESS TO HEALTH (A2H) IN DEVELOPING COUNTRIES: INTELLECTUAL PROPERTY
Respectful and responsible IP
handling essential for improving access
COMMITTED TO IMPROVING THE HEALTH OF UNDER-SERVED POPULATIONSOUR APPROACH BASED ON THE 4 As OF ACCESS*
OUR PROMISE
R&D time, with risks and costs to developing new medicines
Pro-active IP management to find innovative approaches
to broaden access to essential medicines
IP is an enabler for continued long term strategic R&D commitments
2013 WHO Essential Medicines off patent; IP not a developing countries access barrier
WHY INTELLECTUAL PROPERTY (IP) MATTERS
Our Approach
+- 30,000 KNOWN
DISEASES
BUT... ONLY EFFECTIVE
TREATMENTS EXIST FOR +- 1/3RD
10 15
96%
No enforcement or filing of patents
Transparency on patent portfolio
Dialogue with Medicines Patent Pool (MPP) on
expansion of disease scope
IP MANAGEMENT
10-15 years
AVAILABILITY
ACCESSIBILITY
AFFORDABILITY
AWARENESS
MERCK KGaA, DARMSTADT,
GERMANY 4AS OF ACCESS
Merck KGaA, Darmstadt, Germany
PATENT
Supports global Word Trade Organization IP rights standards
including TRIPS and Doha Declaration
We Support Socially Responsible Intellectual Property
Our Patent Commitments In Developing Countries
EXAMPLES OF OUR COMMITMENTS
Developing countries where Merck KGaA, Darmstadt, Germany does not file or enforce patents
Other developing countries
Developed countries
Voluntary licensing agreements focused on improving access ATMI
product development partnerships and technology
transfer agreements
R&D partnerships to address diseases and advance R&D and manufacturing capabilities
Patent pools to improve access to life-saving medicines
Biosimilars in Brazil - Partnership with BioNovis:Joint Venture with 4 Brazilian companies for biosimilar products including technology transfer for drug production
Unique multi-stakeholder dialogue on innovative access and IP:For the first time bringing together external experts in the access and IP field to discuss innovative IP initiatives
WIPO Re:Search:An open innovation platform sponsored by World Intellectual Property Organisation in collaboration with BioVentures for Global Health, for knowledge and IP sharing to accelerate early discovery for infectious diseases.
* To learn more about Our Approach to A2H in developing countries, please see the infographic on Our Approach. For more information on all our A2H Charter papers, please contact [email protected] or visit our A2H website http://www.emdgroup.com/emd/responsibility/access_to_health/access_to_health.html
ATMi = Access to medicine Index 2014 highlighted best practices
WORLD TRADE ORGANISATION
February 2016
Top Related